Share This Page
Drug Price Trends for NDC 52536-0886
✉ Email this page to a colleague
Average Pharmacy Cost for 52536-0886
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VERAPAMIL SR 360 MG CAPSULE | 52536-0886-01 | 4.40180 | EACH | 2025-04-23 |
| VERAPAMIL SR 360 MG CAPSULE | 52536-0886-01 | 4.30226 | EACH | 2025-03-19 |
| VERAPAMIL SR 360 MG CAPSULE | 52536-0886-01 | 4.11307 | EACH | 2025-03-12 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 52536-0886
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| No data available in table | |||||||
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Verapamil Hydrochloride (NDC 52536-0886)
Verapamil hydrochloride, a calcium channel blocker marketed under NDC 52536-0886 by Wilshire Pharmaceuticals, Inc., is a critical therapeutic agent for managing hypertension, angina, and arrhythmias. This delayed-release oral capsule formulation offers sustained pharmacological effects, enhancing patient compliance compared to immediate-release alternatives. The global pharmaceutical market, valued at $1,645.75 billion in 2024, is projected to grow at a 6.12% CAGR through 2030, driven by aging populations and chronic disease prevalence[4]. Within this landscape, Verapamil’s market dynamics reflect broader trends in cardiovascular therapeutics, regulatory pressures, and competitive pricing strategies.
Therapeutic Profile and Regulatory Status of NDC 52536-0886
Pharmacological Mechanism and Clinical Applications
Verapamil hydrochloride inhibits calcium ion influx into cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and myocardial oxygen demand[1][7]. Its delayed-release formulation (NDC 52536-0886) ensures prolonged absorption, making it suitable for chronic hypertension management. The drug’s mechanism of action overlaps with cytochrome P450 3A4 and P-glycoprotein inhibition, necessitating careful consideration of drug-drug interactions[1].
Regulatory and Manufacturing Context
NDC 52536-0886, approved in 1990, remains active in the FDA’s NDC Directory with an expiration date of December 31, 2025, pending renewal[1]. Manufactured by Wilshire Pharmaceuticals, each bottle contains 100 delayed-release capsules, billed per unit (EA) under the 11-digit code 52536088601[1][7]. As a generic product, it competes with branded alternatives like Verelan, though its cost-effectiveness positions it favorably in formulary selections[15].
Global Verapamil Market Dynamics
Market Size and Growth Projections
The Verapamil market was valued at $1.2 billion in 2022 and is projected to reach $1.8 billion by 2030, growing at a 5.5% CAGR[11][14]. This growth is fueled by:
- Aging Demographics: Cardiovascular diseases account for 32% of global mortality, escalating demand for antihypertensives[11].
- Generic Penetration: Patent expirations have enabled widespread generic adoption, reducing costs by 30–80% compared to branded versions[4][15].
- Extended-Release Formulations: NDC 52536-0886’s delayed-release design aligns with trends toward once-daily dosing, improving adherence[1][14].
Regional Market Segmentation
- North America: Dominates with ~30% market share due to high hypertension prevalence (50% of U.S. adults) and advanced healthcare infrastructure[11][15].
- Asia-Pacific: Fastest-growing region (40% share by 2030), driven by rising healthcare access and CVD awareness[14].
- Europe: Holds 20% share, supported by geriatric care initiatives and cost-containment policies favoring generics[4].
Pricing Analysis and Cost Drivers
Current Pricing Benchmarks
While NDC 52536-0886’s exact wholesale price isn’t disclosed, analogous data provides insights:
- NADAC Trends: Wilshire’s Dextroamphetamine Sulfate (NDC 52536-500) shows price volatility, fluctuating between $0.24–$0.59 per unit[12].
- Retail Comparators: Verapamil’s extended-release tablets cost $23.02–$52.17 for 30–100 units, depending on strength[15]. Intravenous formulations average $18 per 2mL vial[15].
- Cost-Plus Models: Online pharmacies offer generics at $9.21–$147.85 for 30-count packs, highlighting retail markup variability[16][18].
Regulatory and Policy Influences
The Inflation Reduction Act’s Medicare Negotiation Program, effective 2026, targets drugs with significant list-price increases (20–55% from 2018–2023)[5]. While Verapamil isn’t among the initial 10 negotiated drugs, future inclusion could cap prices at 38–79% below list rates, pressuring manufacturer margins[5].
Competitive Landscape and Strategic Opportunities
Key Market Players
- Pfizer, Novartis, and Mylan: Control ~45% of the global Verapamil market through diversified portfolios and generics[11][14].
- Wilshire Pharmaceuticals: Leverages niche formulations like NDC 52536-0886 to compete, though smaller market presence necessitates strategic partnerships[1][8].
Innovation and Differentiation
- Combination Therapies: Pairing Verapamil with ACE inhibitors or diuretics could enhance efficacy, justifying premium pricing[14].
- Telemedicine Integration: Remote monitoring platforms improve adherence, potentially increasing prescription volumes for chronic therapies[14].
Price Projections for NDC 52536-0886 (2025–2030)
Baseline Scenario (Stable Regulatory Environment)
- 2025: $0.45–$0.60 per unit, reflecting current NADAC trends[12].
- 2026: +3–5% increase due to inflation and demand growth[4][11].
- 2030: Cumulative rise of 18–22%, reaching $0.53–$0.73 per unit[11].
Risk-Adjusted Scenarios
- Downside (Recession/Economic Contraction): Prices could drop 6–9% if healthcare spending contracts, mirroring 2023’s $25.95 low for similar drugs[3][12].
- Upside (Regulatory Shifts): Medicare negotiation exemptions or expedited approvals might sustain 7–10% annual growth, surpassing $0.80 per unit by 2030[5][14].
Challenges and Mitigation Strategies
Generic Competition and Margin Erosion
With 70% of Verapamil sales from generics, Wilshire must optimize production costs and explore emerging markets to offset price pressures[4][14].
Patient Compliance and Adverse Effects
Side effects like constipation (reported in 30% of users) necessitate patient education initiatives to reduce discontinuation rates[11][14].
Conclusion
NDC 52536-0886 occupies a stable niche within the expanding Verapamil market, supported by aging populations and generic affordability. Price trajectories will hinge on regulatory interventions, competitive dynamics, and adherence to value-based care models. Stakeholders should monitor Medicare policy developments and invest in patient-centric delivery systems to sustain growth.
“The future of cardiovascular drug markets lies in balancing cost containment with therapeutic innovation.” – Grand View Research[4].
Key Takeaways
- Verapamil’s global market will grow at 5.1–5.5% CAGR through 2030.
- NDC 52536-0886’s pricing faces upside from telemedicine adoption and downside from Medicare negotiations.
- Strategic partnerships and combination therapies are critical for differentiation.
FAQs
- What is Verapamil’s primary use?
It treats hypertension, angina, and arrhythmias by relaxing blood vessels. - How does NDC 52536-0886 differ from other Verapamil formulations?
Its delayed-release design ensures prolonged efficacy with once-daily dosing. - Will Medicare negotiations affect Verapamil prices?
Not immediately, but future inclusion in the program could reduce margins. - What drives Verapamil’s market growth?
Aging populations, chronic disease prevalence, and generic accessibility. - How do online pharmacy prices compare to traditional retailers?
They offer 20–50% discounts, e.g., $9.21 vs. $23.02 for 30 tablets[15][18].
References
- https://ndclist.com/ndc/52536-886/package/52536-886-01
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c3d2e99-5351-4442-916a-d2001b0a5f5a
- https://www.youtube.com/watch?v=q7NokNjs60Q
- https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report
- https://aspe.hhs.gov/sites/default/files/documents/3e8abec86039ac0ed674a8c5fac492e3/price-change-over-time-brief.pdf
- https://www.drugpatentwatch.com/p/drug-price/drugname/IBUPROFEN
- https://www.hipaaspace.com/medical_billing/coding/national.drug.codes/52536-886-01
- https://fda.report/NDC/52536-500
- https://www.huduser.gov/portal/publications/pdf/FortWayneIN-CHMA-24.pdf
- https://www.agmanager.info/production-economics/prices-and-price-forecasts/diesel-fuel-price-outlook-2025
- https://www.verifiedmarketreports.com/product/verapamil-market/
- https://ndclist.com/ndc/52536-510/package/52536-510-01/price
- https://media.blueyonder.com/idc-market-analysis-perspective-worldwide-transportation-and-logistics-2024/
- https://github.com/adelanwkadua/Market-Research-Report-List-1/blob/main/verapamil-market.md
- https://www.drugs.com/price-guide/verapamil
- https://www.costplusdrugs.com/medications/verapamil-hcl-er-120mg-capsule-extended-release-verelan/
- https://www.costplusdrugs.com/medications/verapamil-hcl-er-200mg-capsule-extended-release-verelan-pm/
- https://www.costplusdrugs.com/medications/verapamilhcler-180mg-tablet/
- https://www.costplusdrugs.com/medications/verapamil-hcl-er-360mg-capsule-extended-release-verelan/
More… ↓
